AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04706026 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Open Inguinal Hernia Repair - Local Anesthesia
Description: Patients in the local anesthesia arm will receive an injection of a 50:50 mix of 1% lidocaine with epinephrine and 0.25% Marcaine at the surgical site (in the skin and subcutaneous layers + beneath the external oblique aponeurosis). Patients in the local arm will also receive intravenous sedation (Propofol or Precedex) and pain medication (morphine or fentanyl) at the discretion of the attending anesthesiologist.
Study NCT04706026 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inguinal Hernia Repair - General Anesthesia
Description: General anesthesia will be administered at the discretion of the anesthesiologist and will involve a combination of inhaled and intravenous anesthesia.
Study NCT06639711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taurine
Description: Taurine-containing eye drops (VIZILOTON) are applied 4 times daily for a period of one year
Study NCT06530797 — intervention group
Intervention type: DRUG
Intervention: First-line Adebrelimab regiment for advanced stage ES-SCLC
Description: First-line Adebrelimab in any regiment for advanced stage ES-SCLC
Study NCT06530797 — intervention group
Intervention type: DRUG
Intervention: Second-line and beyond Adebrelimab regiment for advanced stage ES-SCLC
Description: Second-line and beyond Adebrelimab in any regiment for advanced stage ES-SCLC
Study NCT05446779 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Adrenal aldosterone synthase (CYP11B2) staining
Description: Immunoshistochemical diagnosis of primary aldosteronism
Study NCT05446779 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Adrenal cortisol synthase (CYP11B1) staining
Description: Immunoshistochemical diagnosis of adrenal hypercortisolism
Study NCT05446779 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Histopathological analysis
Description: Diagnosis of any endocrine neoplasia other than primary aldosteronism or adrenal hypercortisolism
Study NCT06274294 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: CT-P13
Description: Induction treatment.
Study NCT06274294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT-P13
Description: Induction treatment.
Study NCT06163248 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chrono nutrition
Description: An integral nutritional strategy involving timing, order and distribution of macronutrients
Study NCT06163248 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard
Description: Conventional nutritional strategy involving isocaloric distribution with no specific timing
Study NCT05298865 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive imagination stimulation
Description: The intervention messages aim to generate participants' positive mental image toward their life and also to relieve parental stress by shifting their attention to positive life events. The positive affect cues will be developed based on qualitative interviews with 30 parents from our previous study during pandemic and also extended literatures on positive psychology. Our previous qualitative interview aimed to understand parental concerns on flu and COVID-19 vaccination, parental life stressors throughout the pandemic were also explored. The positive cues will be discussed and evaluated by the research team with an aim to cover major positive life events that are personal relevant to parents, including positive social support (friendship), positive family support (family gathering), qualified time spent with children (here we will also embed a gratitude practice to elicit strong positive feelings), and cultivate positive self by imagining achieving personal goals in the future.
Study NCT05298865 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Neutral recall message
Description: The control message aims to equate time and attention as in the intervention group. Therefore, a recall task will be assigned to participants. Brief texts will be provided to guide participants to memorize their life senarios but not to induce emotions. Messages include the following: recall the breakfast and lunch you had yesterday; recall the clothes and shoes you wore yesterday; recall the kitchen in your home; recall one of the chairs in your home; recall the routes to the nearest supermarket and subway of your house.
Study NCT05626842 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Total Diet Replacement (800kcal/day)
Description: The TDR intervention involves a low-calorie, nutritionally complete diet for 12 weeks consuming four meal replacement products exclusively per day, followed by a 4-week food-based reintroduction period; and then weight loss maintenance support monthly for a further 36 weeks. If a patient gains more than 2kg in the maintenance phase, they have the option to follow a TDR for an additional 4 weeks.
Study NCT05247229 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Middle school education program
Description: The intervention assesses the impact of a middle school education program (implemented as an after school program in Sitka, AK and Juneau, AK and during school hours as an elective in Hoonah, AK) on shellfish and toxin knowledge and clam harvesting planned behaviors. The intervention takes place weekly during the school year. The curriculum centers around teaching children about local traditional ecological knowledge and traditional harvesting and gathering practices.
Study NCT06272721 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Griffiths Scale
Description: The Griffiths Mental Development Scales II are key tools for assessing children's psychomotor development from ages 0 to 6, praised for their strong psychometric properties. They evaluate various functional areas through six subscales, combining parental reports and direct observations of the child's behavior. The areas include locomotion, personal-social interaction, learning and language, eye-hand coordination, and performance, excluding the optional practical reasoning section for older children in this study. The Development Quotient (DQ), calculated by comparing mental and chronological ages, indicates developmental progress or delay, with an average score around 100 ± 15.
Study NCT06272721 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Griffiths Scale
Description: The Griffiths Mental Development Scales II are key tools for assessing children's psychomotor development from ages 0 to 6, praised for their strong psychometric properties. They evaluate various functional areas through six subscales, combining parental reports and direct observations of the child's behavior. The areas include locomotion, personal-social interaction, learning and language, eye-hand coordination, and performance, excluding the optional practical reasoning section for older children in this study. The Development Quotient (DQ), calculated by comparing mental and chronological ages, indicates developmental progress or delay, with an average score around 100 ± 15.
Study NCT05327933 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery plus endovascular MMA embolization
Description: A micro catheter is inserted transfemorally into the branches of the middle meningeal artery (MMA) in a minimally invasive manner and the periphery is occluded using polyvinyl alcohol (PVA) particles to prevent future bleeding. If the desired catheter position cannot be achieved due to the anatomical conditions, a more proximal closure of the MMA using Onyx® or micro-electric coils is performed. Embolization of the MMA by PVA particles with sizes between 40-300 µm is preferred over embolization by coils and Onyx®, since the capillary network of the dura is entirely blocked when using particles. In order to identify the vessels to be closed, a digital subtraction angiography (DSA) is performed.
Study NCT05327933 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery alone
Description: Evacuation of cSDH
Study NCT05669534 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: community-friendly health recovery program
Description: Participants will receive 4 weekly 45 minute sessions HIV prevention sessions.
Study NCT05669534 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: community-friendly health recovery program
Description: Participants will receive 4 weekly 45 minute sessions HIV prevention sessions.
Study NCT04941508 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: the mother's recorded voice
Description: Children will be assigned to listen to the mother's recorded voice at 2 times (in the holding area 3 minutes before induction of anesthesia till induction of anesthesia is ended) and (during emergence from anesthesia till complete recovery).
Study NCT04941508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Children will be given a single bolus of dexmedetomidine 0.2 µ/kg IV at 2 times (in the holding area 3 minutes before induction of anesthesia) and (at the end of surgery).
Study NCT04941508 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline 0.9% placebo
Description: Children will be given the same volume of saline at 2 times (in the holding area 3 minutes before induction of anesthesia) and (at the end of surgery).
Study NCT04913194 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ARFID-PTP
Description: ARFID-PTP is a two-session virtual protocol using psychoeducation, parent training skills, and exposure to decrease picky eating symptoms consistent with an ARFID diagnosis.
Study NCT04913194 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: ARFID-PTP
Description: ARFID-PTP is a two-session virtual protocol using psychoeducation, parent training skills, and exposure to decrease picky eating symptoms consistent with an ARFID diagnosis.
Study NCT05259605 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: The goal is to determine whether the new 2021 WHO classification, based on cIMPACT-NOW recommendations, results in more homogeneous patient groups than the old 2016 classification. Furthermore, it will help derive provisional guidelines on how patients with these newly defined tumour entities are best treated. These recommendations will be based on the experience of EORTC investigators with chosen treatments and their experience as reported in this data collection report.
Study NCT05712278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR445419
Description: Cell suspension, by intraveneous (IV) injection
Study NCT05712278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine
Description: Solution for injection , by IV injection
Study NCT05712278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Solution for injection, by IV injection
Study NCT06074354 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention-control group
Description: Participants will receive a one-hour general health promotion session from a nurse and be issued a phone that will deploy the EMA on the same schedule as the intervention arm. They will also receive usual care from the clinics, drop-in center, and shelter recruitment sites. Usual care includes accessing social workers and case managers for immediate housing, food, and clothing needs and assistance in navigating the local Continuum of Care system to access social services.
Study NCT06074354 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MY-RIDE group
Description: MY-RIDE has three main components: 1) One nurse-led face-to-face session; 2) three months of Ecological Momentary Assessments (EMA) with personalized messaging delivered by phone in real-time in response to one's current risk; and 3) access to on-demand healthcare/PrEP navigation and referrals.
Study NCT05029089 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified Entire Papilla Preservation Technique (MEPPT) For Periodontal Regenerative Treatment Of Intrabony Defects.
Description: Surgical approach using modified papilla preservation technique for regenerative periodontal therapy.
Study NCT04743661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan is a semisynthetic water-soluble analog of camptothecin (a plant alkaloid isolated from Camptotheca acuminata). Irinotecan is available in single-dose amber glass vials in 40 mg (2 mL) and 100 mg (5 mL), 300 mg (15 mL), and 500 mg (25 mL).~Patients on Stratum 1 will be given irinotecan at 50 mg/m2/day IV on Days 1 through 5 of each chemotherapy course.
Study NCT04743661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: An orally administered alkylating agent, a second generation imidazotetrazine. A prodrug of MTIC, temozolomide spontaneously decomposes to MTIC at physiologic pH. Exerts its effect by cross-linking DNA. Temozolomide capsules are available in six different strengths (5, 20, 100, 140, 180, 250 mg). The capsules vary in size, color, and imprint according to strength. In the US, capsules are packaged in 5-count and 14-count bottles.~Patients on Stratum 1 will be given temozolomide at 150 mg/m2/dose PO on Days 1-5 of each chemotherapy course.
Study NCT04743661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab is a recombinant humanized anti-vascular endothelial growth factor (anti-VEGF) monoclonal antibody. Bevacizumab is supplied as a clear to slightly opalescent, sterile liquid ready for parenteral administration. Each 400 mg (25 mg/mL, 16 mL fill) glass vial contains bevacizumab with phosphate, trehalose, polysorbate 20, and Sterile Water for Injection.~Patients on Stratum 1 will be given bevacizumab at 10 mg/kg/day IV on Days 1 and 15 of each chemotherapy course, with the exception of the last course of Induction Chemotherapy (i.e., Course 2 or 4) where it will be administered on Day 1 only.
Study NCT04743661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omburtamab I-131
Description: Omburtamab is a murine IgG1 monoclonal antibody (mAb) against B7-H3 (CD276) manufactured by in vivo growth of the hybridoma cell line without the use of animal-derived components. Omburtamab will be radiolabeled with iodine-131 at a designated radiolabeling facility. 131I-omburtamab is supplied as a sterile, injectable, radioactive product in a vial. Each supplied vial will contain enough radioactivity to prepare 50 mCi of 131I-omburtamab, formulated in 3.5-4 mL of solution. 131I-omburtamab should be administered via an intraventricular access device (i.e., Ommaya catheter or programmable VP shunt). Radioimmunotherapy consists of 56 days.~Patients on Stratum 1 will receive a therapeutic dose of 50 mCi cRIT 131I-omburtamab on Days 8 and 36 of Radioimmunotherapy.~Patients on Stratum 2 will receive a therapeutic dose of 50 mCi cRIT 131I-omburtamab on Days 1 and 29 of Radioimmunotherapy.
Study NCT05029089 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified Entire Papilla Preservation Technique (MEPPT) For Periodontal Regenerative Treatment Of Intrabony Defects.
Description: Surgical approach using modified papilla preservation technique for regenerative periodontal therapy.
Study NCT05029089 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Emdogain (EMD), Biomaterials (allograft, subepithelial connective tissue graft/sCTG)
Description: Surgical approach using modified papilla preservation technique and devices for regenerative periodontal therapy.
Study NCT05669534 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis
Description: Participants will be prescribed Pre-exposure prophylaxis (PrEP) is a biomedical intervention.
Study NCT05669534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis
Description: Participants will be prescribed Pre-exposure prophylaxis (PrEP) is a biomedical intervention.
Study NCT04743661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liothyronine
Description: Liothyronine (or equivalent) will be given as premedication for 131I-omburtamab to prevent thyroid accumulation. Liothyronine (or equivalent) will be administered at 25 µg PO, NG, or G-tube (if weight \< 25 kg) or 50 µg PO, NG, or G-tube (if weight ≥ 25 kg) daily starting on Day 1 of Radioimmunotherapy (for Stratum 1 patients) or Day 1 of Dosimetry (for Stratum 2 patients), with a mandated minimum of 7 days before each 131I-omburtamab injection and 14 days after each 131I-omburtamab injection. On the day of the 131I-omburtamab injection, administer any time before the injection.
Study NCT04743661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSKI
Description: SSKI (potassium iodide) will be given as premedication for 131I-omburtamab to prevent thyroid accumulation. SSKI (potassium iodide) will be administered as 7 drops (\~0.35 mL) PO, NG, or G-tube daily starting on Day 1 of Radioimmunotherapy (for Stratum 1 patients) or Day 1 of Dosimetry (for Stratum 2 patients), with a mandated minimum of 7 days before each 131I-omburtamab injection and 14 days after each 131I-omburtamab injection. On the day of the 131I-omburtamab injection, administer any time before the injection.
Study NCT04891484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron group
Description: patients will be injected with 4 mg Ondansetron diluted with normal saline IV 5 minutes before spinal anesthesia
Study NCT04891484 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline group
Description: patients will be injected with 10 ml normal saline intravenous 5 min before spinal anesthesia
Study NCT05037617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Continuation or discontinuation of oxytocin during the active first stage of labor (≥6 cm dilation).
Description: At the intervention site (Foothills Medical Centre), for participants who consent to being part of the trial, once a patient is found to be >= 6 cm dilation, the study medication will be initiated. Pharmacy will make up identical vials of oxytocin or saline, which will be numbered according to the random allocation sequence created by the study statistician.~The intervention will be continued until delivery unless contractions decrease to less than 2 in 10 minutes or if no further cervical dilation is noted 4 hours after discontinuation.
Study NCT05037617 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Continuation or discontinuation of oxytocin during the active first stage of labor (≥6 cm dilation).
Description: At the intervention site (Foothills Medical Centre), for participants who consent to being part of the trial, once a patient is found to be >= 6 cm dilation, the study medication will be initiated. Pharmacy will make up identical vials of oxytocin or saline, which will be numbered according to the random allocation sequence created by the study statistician.~The intervention will be continued until delivery unless contractions decrease to less than 2 in 10 minutes or if no further cervical dilation is noted 4 hours after discontinuation.
Study NCT04743661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be given as premedication for 131I-omburtamab to prevent possible meningeal inflammatory reaction. Starting within 24 hours prior to each 131I-omburtamab injection, dexamethasone will be administered orally at 0.5 mg (if weight \< 15 kg) or 1 mg (if weight ≥ 15 kg) twice-daily doses for a total of 6 doses to alleviate infusion-related AEs: Two doses starting 24 hours pre-131I-omburtamab injection, two doses on the day of the injection (can be given before or after), and two doses 24 hours post-131I-omburtamab injection.
Study NCT04743661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antipyretic
Description: An antipyretic (e.g., oral acetaminophen \[15 mg/kg, 650 mg maximum\] or equivalent) will be given as premedication for 131I-omburtamab within 1 to 3 hours before each 131I-omburtamab injection.
Study NCT04743661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antihistamine
Description: An antihistamine (e.g., IV diphenhydramine \[1 mg/kg, 50 mg maximum\] or equivalent) will be given as premedication for 131I-omburtamab within 1 to 3 hours before each 131I-omburtamab injection.
Study NCT04743661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-emetics
Description: An anti-emetic (e.g., IV ondansetron \[0.25 mg/kg, 16 mg maximum\] or equivalent) will be given as premedication for 131I-omburtamab within 1 to 3 hours before each 131I-omburtamab injection.
Study NCT04761835 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Peanut powder or peanut butter
Description: Commercially available peanut powder or peanut butter.
Study NCT05029089 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified Entire Papilla Preservation Technique (MEPPT) with Emdogain For Periodontal Regenerative Treatment Of Intrabony Defect
Description: Surgical approach using modified papilla preservation technique and Emdogain for regenerative periodontal therapy.
Study NCT05029089 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified Entire Papilla Preservation Technique (MEPPT) with Emdogain and Allograft For Periodontal Regenerative Treatment Of Intrabony Defect
Description: Surgical approach using modified papilla preservation technique and Emdogain and Allograft for regenerative periodontal therapy.
Study NCT06151236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combination
Description: Dual inhibition of the distinct LAG3 and PD-1 checkpoint pathways
Study NCT05010889 — intervention group
Intervention type: PROCEDURE
Intervention: Peroral endoscopic myotomy (POEM)
Description: POEM is performed as previously described by Inoue et al (Endoscopy 2010), including four main steps mucosal incision, submucosal tunneling, myotomy and mucosal entry closure.
Study NCT04663555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Patients in the intervention group after randomization will receive dexamethasone 20 mg intravenously once daily on day 1-5, followed by dexamethasone 10 mg intravenously once daily on day 6-10. If successful extubation occurs before day 10, treatment with dexamethasone is withdrawn.